Day One Biopharmaceuticals, Inc.
DAWN
$6.43
$0.132.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.76M | 29.21M | 93.76M | 8.19M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.76M | 29.21M | 93.76M | 8.19M | -- |
| Cost of Revenue | 2.88M | 2.98M | 1.59M | 707.00K | -- |
| Gross Profit | 27.88M | 26.23M | 92.17M | 7.49M | -- |
| SG&A Expenses | 29.33M | 29.74M | 28.97M | 30.19M | 26.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.83M | 94.54M | 64.13M | 123.00M | 61.77M |
| Operating Income | -41.07M | -65.33M | 29.64M | -114.81M | -61.77M |
| Income Before Tax | -36.00M | -59.24M | 36.16M | -2.86M | -62.41M |
| Income Tax Expenses | -- | 6.47M | -882.00K | 1.55M | -- |
| Earnings from Continuing Operations | -36.00M | -65.71M | 37.04M | -4.41M | -62.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.00M | -65.71M | 37.04M | -4.41M | -62.41M |
| EBIT | -41.07M | -65.33M | 29.64M | -114.81M | -61.77M |
| EBITDA | -40.25M | -64.71M | 30.24M | -114.49M | -61.74M |
| EPS Basic | -0.35 | -0.64 | 0.38 | -0.05 | -0.72 |
| Normalized Basic EPS | -0.22 | -0.36 | 0.23 | -0.02 | -0.41 |
| EPS Diluted | -0.35 | -0.64 | 0.38 | -0.05 | -0.72 |
| Normalized Diluted EPS | -0.22 | -0.36 | 0.23 | -0.02 | -0.41 |
| Average Basic Shares Outstanding | 102.71M | 102.44M | 96.62M | 87.12M | 86.68M |
| Average Diluted Shares Outstanding | 102.71M | 102.44M | 96.94M | 87.12M | 86.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |